Nonalcoholic Fatty Liver Disease: A Global Perspective

• Published in: Clinical therapeutics Vol. 43; no. 3; pp. 473 - 499
• Main Authors: Wong, Wei-Kei, Chan, Wah-Kheong
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-03-2021; Elsevier Limited
• Subjects: Age groups; Cultural differences; Diabetes; Diabetes mellitus; Epidemiology; Estrogens; Fatty liver; GDP; Gene polymorphism; Genetics; Genotype & phenotype; Gross Domestic Product; incidence; lean; Liver; Liver cancer; Liver diseases; Meta-analysis; Metabolic syndrome; Minority & ethnic groups; Obesity; Polymorphism; prevalence; Risk analysis; Risk factors; Systematic review; Asia; United States > US; Europe; China; Japan; Africa; North America; epidemiology; prevalence; genetics; lean; incidence
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2021.01.007

The prevalence of nonalcoholic fatty liver disease (NAFLD) has been increasing over the years and is now as high in Asia as in the Western world, so much so that it should no longer be considered a Western disease. In fact, China is expected to have the largest increase in the number of NAFLD cases in the coming years. The increase in prevalence of NAFLD in Asia lags behind that of the Western world; thus, there will be a lag in more severe liver disease in Asia despite a similar prevalence of the disease. NAFLD is more prevalent among patients with diabetes mellitus, which is also an important risk factor for more severe liver disease. Patients with diabetes mellitus thus represent an important target for screening for NAFLD and more severe liver disease. Although the PNPLA3 gene polymorphism is the most studied in NAFLD, it is increasingly clear that the cumulative effect of multiple genes likely predisposes to NAFLD and more severe liver disease in the different ethnic groups, and polygenic risk scores are emerging. Lean NAFLD has been largely reported in Asia but is increasingly recognized worldwide. Multiple risk factors have been identified for the disease that manifests in metabolically unhealthy normal weight individuals; however, it responds to lifestyle intervention, similar to the disease in obese individuals. Lastly, the newer term “metabolic dysfunction–associated fatty liver disease” provides a more accurate reflection of the disease, giving more focus to clinicians and researchers in tackling this increasingly common and challenging disease.